Neurocrine Acquiring Soleno Therapeutics for $2.9B: Employee Rights
Is Soleno Therapeutics Being Acquired?
Yes — Neurocrine Biosciences has entered into a “definitive agreement” to acquire Soleno Therapeutics in a deal valued at approximately $2.9 billion.
Through a subsidiary, Neurocine will pay $53 in cash for each outstanding share of Soleno.
“This transaction will advance [our] mission to deliver life-changing treatments while accelerating our revenue growth and portfolio diversification strategy,” Dr. Kyle W. Gano, CEO of Neurocrine, said in a joint news release on April 6, 2026.
The transaction, subject to regulatory approval, is expected to close within 90 days.
Our Sale of Business Guides for Ontario, Alberta, and British Columbia (BC) break down everything that non-unionized employees need to know.
Disclaimer: The materials above are provided as general information about the rights of non-unionized employees in Canada. It is not specific to any one company and SHOULD NOT be read as suggesting any improper conduct on the part of any specific employer, or a relationship between Samfiru Tumarkin LLP and a specific employer.